| Molecular mechanisms underlying ErbB2/HER2 action in breast cancer D Harari, Y Yarden Oncogene 19 (53), 6102-6114, 2000 | 896 | 2000 |
| Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase D Harari, E Tzahar, J Romano, M Shelly, JH Pierce, GC Andrews, ... Oncogene 18 (17), 2681-2689, 1999 | 437 | 1999 |
| SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution J Zahradník, S Marciano, M Shemesh, E Zoler, D Harari, J Chiaravalli, ... Nature microbiology 6 (9), 1188-1198, 2021 | 347 | 2021 |
| Hsp90 recognizes a common surface on client kinases A Citri, D Harari, G Shohat, P Ramakrishnan, J Gan, S Lavi, M Eisenstein, ... Journal of biological chemistry 281 (20), 14361-14369, 2006 | 263 | 2006 |
| Ligand‐independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin‐interacting motif targets ubiquitylation … M Katz, K Shtiegman, P Tal‐Or, L Yakir, Y Mosesson, D Harari, Y Machluf, ... Traffic 3 (10), 740-751, 2002 | 184 | 2002 |
| ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture MA Huotari, PJ Miettinen, J Palgi, T Koivisto, J Ustinov, D Harari, ... Endocrinology 143 (11), 4437-4446, 2002 | 123 | 2002 |
| Receptor density is key to the alpha2/beta interferon differential activities I Moraga, D Harari, G Schreiber, G Uzé, S Pellegrini Molecular and cellular biology 29 (17), 4778-4787, 2009 | 120 | 2009 |
| SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon M Shemesh, TE Aktepe, JM Deerain, JL McAuley, MD Audsley, CT David, ... PLoS pathogens 17 (8), e1009800, 2021 | 119 | 2021 |
| Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity BS Kochupurakkal, D Harari, A Di-Segni, G Maik-Rachline, L Lyass, ... Journal of Biological Chemistry 280 (9), 8503-8512, 2005 | 116 | 2005 |
| Stochastic receptor expression determines cell fate upon interferon treatment D Levin, D Harari, G Schreiber Molecular and cellular biology 31 (16), 3252-3266, 2011 | 114 | 2011 |
| c-Cbl is a suppressor of the neu oncogene G Levkowitz, S Oved, LN Klapper, D Harari, S Lavi, M Sela, Y Yarden Journal of Biological Chemistry 275 (45), 35532-35539, 2000 | 92 | 2000 |
| Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands A Apelbaum, G Yarden, S Warszawski, D Harari, G Schreiber Molecular and cellular biology 33 (4), 800-814, 2013 | 84 | 2013 |
| Hsp90 increases LIM kinase activity by promoting its homo‐dimerization R Li, J Soosairajah, D Harari, A Citri, J Price, HL Ng, CJ Morton, ... The FASEB journal 20 (8), 1218-1220, 2006 | 73 | 2006 |
| Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis D Harari, N Kuhn, R Abramovich, K Sasson, AL Zozulya, P Smith, ... Journal of Biological Chemistry 289 (42), 29014-29029, 2014 | 68 | 2014 |
| Characterization of a vasa‐like gene from the pacific white shrimp Litopenaeus vannamei and its expression during oogenesis ED Aflalo, A Bakhrat, S Raviv, D Harari, A Sagi, U Abdu Molecular Reproduction and Development: Incorporating Gamete Research 74 (2 …, 2007 | 64 | 2007 |
| Bridging the species divide: transgenic mice humanized for type-I interferon response D Harari, R Abramovich, A Zozulya, P Smith, S Pouly, M Köster, H Hauser, ... PloS one 9 (1), e84259, 2014 | 58 | 2014 |
| FGF plays a subtle role in oligodendrocyte maintenance in vivo D Harari, D Finkelstein, O Bernard Journal of neuroscience research 49 (4), 404-415, 1997 | 23 | 1997 |
| Growth factor which acts through erb b-4 rtk D Harari, Y Yarden US Patent 7,094,882, 2006 | 18* | 2006 |
| A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis D Harari, I Orr, R Rotkopf, SE Baranzini, G Schreiber Human Molecular Genetics 24 (11), 3192-3205, 2015 | 17 | 2015 |
| Fine tuning of a type 1 interferon antagonist V Urin, D Levin, N Sharma, D Harari, G Schreiber PLoS One 10 (7), e0130797, 2015 | 14 | 2015 |
Gideon schreiberweizmann or hadassah or cambridge在 weizmann.ac.il 的电子邮件经过验证
